U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H22N2O2.ClH
Molecular Weight 418.915
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TALNETANT HYDROCHLORIDE

SMILES

Cl.CC[C@H](NC(=O)C1=C(O)C(=NC2=C1C=CC=C2)C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=BHCSUEHQURQVLD-BDQAORGHSA-N
InChI=1S/C25H22N2O2.ClH/c1-2-20(17-11-5-3-6-12-17)27-25(29)22-19-15-9-10-16-21(19)26-23(24(22)28)18-13-7-4-8-14-18;/h3-16,20,28H,2H2,1H3,(H,27,29);1H/t20-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C25H22N2O2
Molecular Weight 382.4544
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800009015 https://en.wikipedia.org/wiki/Talnetant

Talnetant (SB-223412) is a selective, orally active neurokinin 3 receptor antagonist and is under development for the potential treatment of several disorders, including irritable bowel syndrome, schizophrenia, chronic obstructive pulmonary disease, cough, overactive bladder and urinary incontinence. The most common adverse effects were headache, fatigue, and nausea.

CNS Activity

Curator's Comment: SB223412 crosses the blood-brain barrier to a significant extent.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.0 nM [Ki]
144.0 nM [Ki]
100.0 µM [Ki]
Conditions
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.56 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TALNETANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
600 mg 2 times / day multiple, oral
Studied dose
Dose: 600 mg, 2 times / day
Route: oral
Route: multiple
Dose: 600 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 275
Health Status: unhealthy
Condition: schizophrenia
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 275
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/17727393 25 or 100 mg over 14-17 days.
0.1 mg to 1000 mg as single doses; up to 800 mg twice daily on repeat doses.
Route of Administration: Oral
In Vitro Use Guide
SB223412 antagonized senktide-induced contraction of rabbit isolated iris sphincter muscle (KB = 1.6 nM), and inhibited NK-3 receptorinduced membrane depolarization in guinea-pig bronchial parasympathetic ganglia and substantia nigra pars compacta in guinea pig. SB223412 inhibited senktide-induced miosis in rabbits when given iv (ED50 = 0.44mg/kg) and by 53% when given orally (25 mg/kg, PO).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:59:19 GMT 2023
Edited
by admin
on Fri Dec 15 15:59:19 GMT 2023
Record UNII
C1ZIJ8F59E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TALNETANT HYDROCHLORIDE
USAN   WHO-DD  
USAN  
Official Name English
Talnetant hydrochloride [WHO-DD]
Common Name English
TALNETANT HYDROCHLORIDE [USAN]
Common Name English
(S)-3-HYDROXY-2-PHENYL-N-(1-PHENYLPROPYL)-4-QUINOLINECARBOXAMIDE MONOHYDROCHLORIDE
Systematic Name English
SB-223412-A
Code English
Classification Tree Code System Code
NCI_THESAURUS C29698
Created by admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL10188
Created by admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
PRIMARY
DRUG BANK
DBSALT002012
Created by admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
PRIMARY
FDA UNII
C1ZIJ8F59E
Created by admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
PRIMARY
CAS
204519-66-4
Created by admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
PRIMARY
PUBCHEM
9844955
Created by admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
PRIMARY
EPA CompTox
DTXSID50942628
Created by admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
PRIMARY
USAN
KK-81
Created by admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
PRIMARY
NCI_THESAURUS
C152498
Created by admin on Fri Dec 15 15:59:20 GMT 2023 , Edited by admin on Fri Dec 15 15:59:20 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY